<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">Colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) is the third most commonly diagnosed <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> and the second highest cause of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> <z:hpo ids='HP_0011420'>death</z:hpo> in the UK </plain></SENT>
<SENT sid="1" pm="."><plain>Most cases occur in people over 50 years and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> often co-exists with other lifestyle related disorders including <z:hpo ids='HP_0001513'>obesity</z:hpo>, type 2 <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> (T2DM) and <z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">cardiovascular disease</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e>) </plain></SENT>
<SENT sid="2" pm="."><plain>These diseases share risk factors related to the <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> including <z:mp ids='MP_0001264'>large body size</z:mp>, abnormal <z:chebi fb="23" ids="18059">lipids</z:chebi> and markers of <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> indicating common aetiological pathways </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS/DESIGN: This 3 year study will be a two-arm, multicentre, randomised controlled trial comparing the BeWEL lifestyle (diet, physical activity and behaviour change) programme against usual care </plain></SENT>
<SENT sid="4" pm="."><plain>The pre-trial development will take 6 months and participants will be recruited over a 12 month period and undertake the intervention and follow up for 12 months (total 24 months recruitment and intervention implementation) with a further 6 months for data collection, analysis and interpretation.Four hundred and fifty two participants who have had a colorectal <z:mpath ids='MPATH_270'>adenoma</z:mpath> detected and removed (through the national colorectal screening programme) will provide 80% power to detect a <z:hpo ids='HP_0001824'>weight loss</z:hpo> of 7% over 12 months.Primary outcomes are changes in body weight and waist circumference </plain></SENT>
<SENT sid="5" pm="."><plain>Secondary outcomes will include <z:e sem="disease" ids="C0850624" disease_type="Disease or Syndrome" abbrv="">cardiovascular risk factors</z:e>, psycho-social measures and intervention costs </plain></SENT>
<SENT sid="6" pm="."><plain>DISCUSSION: The results from this study will enhance the evidence base for lifestyle change in patients at higher risk of <z:hpo ids='HP_0011010'>chronic</z:hpo> disease including <z:hpo ids='HP_0001513'>obesity</z:hpo> related <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e>.International Standard Randomised Controlled Trials No: ISRCTN53033856 </plain></SENT>
</text></document>